T1	Participants 111 136	granulocytopenic patients
T2	Participants 413 438	granulocytopenic patients
T3	Participants 440 631	Patients were stratified into two groups: favorable-prognosis, group 1 (carcinoma, lymphoma, multiple myeloma), or unfavorable-prognosis, group 2 (acute leukemia, bone marrow transplantation)
